Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings Inc shows a promising outlook as the company's Precision Diagnostic products, particularly POSLUMA, are projected to capture a higher market share and revenue growth in PSMA PET imaging, with expectations of a shift from a low-single-digit to a high-single-digit percentage share by 2025. Additionally, the introduction of a new Pylarify formulary is expected to enhance production capacity by approximately 50%, combined with three years of TPT eligibility, which should invigorate growth in this segment starting in late 2026. Furthermore, any potential growth from non-Pylarify segments may significantly exceed current modeling expectations, providing additional momentum for higher earnings per share in 2026 and 2027.

Bears say

Lantheus Holdings Inc has experienced a significant decline in revenue from its Pylarify product, reporting $260 million, which is an 8% year-over-year decrease and approximately $14 million below consensus expectations. Additionally, unit growth fell short at only 2% year-over-year, coupled with a notable price headwind of 10% during the quarter, further exacerbating the company's challenges. With lowered growth forecasts for 2025-2026 and a growth profile that is now trailing behind profitable SMID MedTech peers, Lantheus's long-term financial performance appears to be under strain.

Lantheus Holdings (LNTH) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 6 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.